CN101892181A - Streptoseomycin and preparation method and application thereof - Google Patents
Streptoseomycin and preparation method and application thereof Download PDFInfo
- Publication number
- CN101892181A CN101892181A CN201010180437.XA CN201010180437A CN101892181A CN 101892181 A CN101892181 A CN 101892181A CN 201010180437 A CN201010180437 A CN 201010180437A CN 101892181 A CN101892181 A CN 101892181A
- Authority
- CN
- China
- Prior art keywords
- streptoseomycin
- medicinal extract
- chloroform
- methyl alcohol
- substratum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000003115 biocidal effect Effects 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 12
- 241001245594 Streptomyces seoulensis Species 0.000 claims abstract description 10
- 238000000855 fermentation Methods 0.000 claims abstract description 6
- 230000004151 fermentation Effects 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 66
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 34
- 239000000284 extract Substances 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 241001655322 Streptomycetales Species 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 6
- 108010016626 Dipeptides Proteins 0.000 claims description 3
- 241000995704 Fenneropenaeus chinensis Species 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000002024 ethyl acetate extract Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims 4
- 241001446247 uncultured actinomycete Species 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 150000002611 lead compounds Chemical class 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 229920001817 Agar Polymers 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000238557 Decapoda Species 0.000 description 4
- 230000003103 anti-anaerobic effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 238000002814 agar dilution Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 241001494424 [Eubacterium] brachy Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention belongs to the biological pharmacy technical field, in particular relates to streptoseomycin extracted from marine actinomycete streptomyces seoulensis liquid fermentation as well as preparation method and application thereof. Streptoseomycin is obtained by separation, purification and fermentation on streptomyces seoulensis from ocean. Streptoseomycin has strong inhibition function on anaerobe and has no toxicity on cell, thus streptoseomycin can be taken as lead compound of antibiotic production and can be applied in preparation of antibiotic medicine.
Description
Technical field
The invention belongs to biological pharmacy technical field, be specifically related to the Streptoseomycin (streptoseomycin) that from marine actinomycete (Streptomyces seoulensis) liquid fermentate, extracts and preparation method thereof and application.
Background technology
Though the secondary metabolite of microorganism is widely studied, the meta-bolites of some special border microorganisms does not cause that still people enough pay attention to.The singularity of ocean environment has brought up the metabolic way and the meta-bolites of marine actinomycete uniqueness.People constantly search out from the actinomycetes of various ocean environment and can produce the microbiotic with novel mechanism of action in recent years.Except microbiotic, marine actinomycete can also produce the inhibitor of plurality of enzymes, and the diversity of marine actinomycete provides an abundant source for secondary metabolite.
Be extensive use of along with antibiotic, the pathogenic bacterium resistance sharply increases, and original microbiotic curative effect reduces significantly, and new disease constantly occurs, all development has brought great challenge to microbiotic for these, finds that novel bacterial becomes exigence to seek new antibiotic.Marine actinomycete may be the antibiotic important channel of screening.Yet up to the present, Shang Weijian separates antibiotic report from Seoul streptomycete (Streptomyces seoulensis).
Summary of the invention
The problem that the present invention need solve is:
1. the Streptoseomycin with anti-microbial activity (streptoseomycin) is provided.
2. the method for provide a kind of extraction, separating Streptoseomycin (streptoseomycin).
3. the application of Streptoseomycin (streptoseomycin) in the preparation antibiotic medicine is provided.
The present invention is achieved by following technical proposals.
Streptoseomycin of the present invention (streptoseomycin) separates obtaining from marine actinomycete liquid fermenting extract, its structural formula is:
Streptoseomycin
Single crystal structure figure sees Figure of description 1.
The preparation method of Streptoseomycin (Streptoseomycin) comprises the steps:
1. fresh Seoul streptomycete thalline piece that separation, purifying obtain from prawn (Penaeus chinensis) enteron aisle is inoculated into Gao Shi I substratum (Zulkovsky starch 20g, KNO
31g, NaCl 0.5g, K
2HPO
43H
2O 0.5g, MgSO
47H
2O 0.5g, FeSO
47H
2O 0.01g, 1L distilled water) in, on shaking table, under 150rpm, 28 ℃ of conditions, cultivate 5 days as seed liquor;
2. then seed liquor is inoculated in Martin's substratum, 150rpm, 20-30 ℃ of condition bottom fermentation 10 days;
3. step 2 gained fermented liquid is filtered through gauze, filtrate is used ethyl acetate extraction, the dry black crude extract F1 that gets of vacuum concentration;
4. crude extract F1 is suspended in water, uses sherwood oil, ethyl acetate extraction successively, the gained acetic acid ethyl acetate extract through concentrate medicinal extract F2;
5. medicinal extract F2 is carried out silica gel column chromatography, use the chloroform of 4 times of volumes successively, chloroform: methyl alcohol=100: 1, chloroform: methyl alcohol=100: 2, chloroform: methyl alcohol=100: 4, carry out wash-out, (chloroform: methyl alcohol) section obtains black medicinal extract F3 to concentrate 100: 4;
6. then medicinal extract F3 is carried out Sephadex LH-20 and separate (elutriant chloroform: methyl alcohol=1: 1) merge green fluorescence part elutriant and get faint yellow medicinal extract F4;
7. to medicinal extract F4, ODS separates with reversed-phase column, carries out wash-out with 55% methyl alcohol earlier and removes the decyclization dipeptides, uses 65% methanol-eluted fractions then, merges green fluorescence part elutriant and gets faint yellow solid F5;
8. to medicinal extract F5, with high pressure lipuid chromatography (HPLC) (chromatographic column: Allsphere ODS-2.5mm (250R4.6mm) column; Moving phase: methanol=60/40 (v/v) flow velocity: 2.0mL/min) separation obtains Streptoseomycin streptoseomycin (retention time t
R=38.2min).
Streptoseomycin of the present invention (streptoseomycin) has very strong restraining effect to anerobe, and do not have cytotoxicity, therefore Streptoseomycin (streptoseomycin) can be used as a kind of microbiotic of novelty, and is applied in the preparation microbiotic; This compound has very strong green fluorescence simultaneously, is expected to further investigate the antibiotic mechanism of action of this class.
Compared with prior art, the present invention has following outstanding advantage:
1. Streptoseomycin of the present invention (streptoseomycin) is the compound of novel structure, can be prepared into new antibiotic or lead compound.Overcome the shortcoming of existing antibiotic resistance.
2. Streptoseomycin of the present invention (streptoseomycin) can utilize microorganism to carry out liquid fermenting production, and technology is easy, and the cycle is short, and cost is low, and it is guaranteed to originate.
Description of drawings
Fig. 1 is the single crystal structure figure of Streptoseomycin (streptoseomycin).
Embodiment
Can further understand the present invention by specific embodiment given below.But they are not limitation of the invention.
Embodiment 1: the isolation and purification of Seoul streptomycete of marine source (Streptomyces seoulensis)
Under aseptic condition, dissect prawn (Penaeus chinensis), with the surface sterilization 2 minutes in 75% alcohol of the prawn enteron aisle that takes out, rinsed with sterile water 3 times, after add a small amount of sterilized water and in aseptic mortar, grind, with sterilized water the lapping liquid gradient dilution is become 10
-1, 10
-2, 10
-3, 10
-4, get 0.2 milliliter of each gradient dilution liquid respectively and coat Gao Shi I substratum (Zulkovsky starch 20g, KNO
31g, NaCl 0.5g, K
2HPO
43H
2O 0.5g, MgSO
47H
2O 0.5g, FeSO
47H
2O0.01g, 1L distilled water) in, place 28 ℃ of thermostat containers to cultivate, after treating that bacterium colony grows, picking spore purifying is cultivated, and obtains shrimp enteron aisle actinomycetes, be accredited as Seoul streptomycete (Streptomyces seoulensis) through Institute of Microorganism, Academia Sinica, (address: the Yard 1, BeiChen xi Road, Chaoyang District, Beijing City), deposit number is CGMCC No.3689, and preservation date is on March 25th, 2010 now to be deposited in DSMZ of Institute of Microorganism, Academia Sinica.
Embodiment 2: the liquid fermenting of Seoul streptomycete of marine source (Streptomyces seoulensis)
Seoul streptomycete (Streptomyces seoulensis) of activation marine source, fresh thalline piece is inoculated in the 1000mL Erlenmeyer flask, every bottle of Gao Shi substratum that contains 400mL, inoculation 5-6 bottle is on shaking table, under 150rpm, 28 ℃ of conditions, cultivate 5 days as seed liquor, then the 20mL seed liquor is inoculated in the 1000mL Erlenmeyer flask of the Gao Shi that contains 400mL or Martin's substratum, 150rpm, 20-30 ℃ of condition bottom fermentation 8 days.
Embodiment 3: the extraction of Streptoseomycin (streptoseomycin) with separate
The gained fermented liquid filters through gauze among the embodiment 2, and filtrate is used ethyl acetate extraction, the dry black crude extract F1 that gets of vacuum concentration.F1 is suspended in water with crude extract, use sherwood oil successively, ethyl acetate extraction, the gained acetic acid ethyl acetate extract through concentrate medicinal extract F2, medicinal extract F2 is carried out silica gel column chromatography, use the chloroform of 4 times of volumes successively, chloroform: methyl alcohol=100: 1, chloroform: methyl alcohol=100: 2, chloroform: methyl alcohol=100: 4, carry out wash-out, (chloroform: methyl alcohol) section obtains black medicinal extract F3 to concentrate 100: 4, then medicinal extract F3 is carried out Sephadex LH-20 and separate (elutriant chloroform: methyl alcohol=1: 1) merge green fluorescence part elutriant and get faint yellow medicinal extract F4, to medicinal extract F4, ODS separates with reversed-phase column, carries out wash-out with 55% methyl alcohol earlier and removes the decyclization dipeptides, use 65% methanol-eluted fractions then, merge green fluorescence part elutriant and get faint yellow solid F5, to medicinal extract F5, with high pressure lipuid chromatography (HPLC) (chromatographic column: Allsphere ODS-2.5mm column; Moving phase: methanol=60/40 (v/v), flow velocity: 2.0mL/min) separation obtains Streptoseomycin streptoseomycin (retention time t
R=38.2min).
Embodiment 4: the structure of Streptoseomycin (streptoseomycin) is identified
The structure of Streptoseomycin (streptoseomycin) be based on they mass spectrum, nuclear magnetic resonance spectrum, the analysis of X-ray single crystal diffraction and Mosher ' s method and definite.
The spectroscopy data are as follows:
Streptoseomycin (streptoseomycin), clear crystal has stronger green fluorescence under ultraviolet, fusing point (m.p.): 268-270 ℃;
(c=0.080, MeOH); CD (MeOH, c=6.6 * 10
-3): λ (Δ ε)=361sh (11.97) 288 (+1.63), 22sh (+2.30), 224 (9.40mol
-1Dm
3Cm
-1);
1H and
13C NMR data see Table 1; IR:v (cm
-1)=3462,3426,3245,2896,1769,1724,1695,1641,1594,1263,1206,1176,1106,1023,754; UV/Vis (MeOH): λ
Max(ε)=358 (2305), 293 (454), 207nm (10891mol
-1Dm
3Cm
-1); HR-ESIMS:m/z:calcd for
C
31H
37O
11NNa：622.2261；found：622.2262[M+Na]
+.
The NMR data of table 1. Streptoseomycin
Table?1.NMR?spectral?data?of?streptoseomycin?in?DMSO-d6
S: unimodal, d: doublet, t: triplet, dd: quartet, m: multiplet, br: wide unimodal
The X-ray single crystal diffraction of Streptoseomycin (streptoseomycin) is analyzed: C
31H
37NO
11, M599, spacer P2 (1), unit cell parameters a=12.816 (2), b=11.607 (2),
α=90.00 °, β=108.12 (3) °, γ=90.00 °; Unit cell volume
Molecule number Z=4 in the structure cell.R
fBe respectively 0.0696,0.1102 with the Rw value.With MoK α radiation, graphite monochromator.Use the ω scan mode, obtain 3699 of independent point diffractions.On microcomputer, parse the single crystal structure (seeing accompanying drawing 1) of Streptoseomycin (streptoseomycin) with direct method (SHELXS-97).
Embodiment 5:MIC method is measured Streptoseomycin (streptoseomycin) anti-anaerobic activity
1) preparation of substratum
Strengthen and add 5% (v/v) dissolving sheep blood, protohemine 5 μ g/ml and 1 μ g/ml vitamin K in the cloth Lu Shi agar
1
2) preparation of agar dilution flat board
The antibiotic solution that at first prepares the test usefulness of different concns reaches the reinforcement cloth Lu Shi agar for preparing test usefulness in advance.Preparation contains the antibiotic agar plate of different concns then.Concrete steps are as follows: good each antibiotic concentration of mark on every flat board is positioned on the horizontal table top then.The reinforcement cloth Lu Shi agar of fusing is cooled to about 50 ℃, the microbiotic that adds different concns, add 5% (v/v) dissolving sheep blood simultaneously, mixing is noted not producing bubble gently, pours in the flat board then, it is solidified, can be placed in the aseptic laminar flow cupboard and flat board is covered half-open, or 35 ℃ hatch 30min, makes its surface drying.
3) inoculation method and inoculation bacterium amount
At first mark is inoculated the site of bacterium well on flat board, and using content is the multiple spot inoculator of 1～2 μ l, dips in directly to be added in agar surface after getting bacterium liquid, and every final inoculation bacterium amount is 10
5CFU.
4) agar dilution drug sensitive test
At first the dilution microbiotic of difference is added and melted and be cooled in the agar about 50 ℃, pour plate behind the mixing, after treating that it solidifies, using inoculator will inoculate standardized tested bacterial strain bacteria suspension is seeded in respectively and contains on the different antibiotic flat board, after inoculation, will inoculate flat board in the 30min and put into oxygen-free environment, The faster the better, in order to avoid the anerobe death extremely responsive to oxygen.After hatching 48h, the flat board of visual control inoculation, the minimum antibiotic concentration of energy bacteria growing inhibiting can be reported as antibiotic MIC.
Anti-anaerobic activity test result (table 2) shows: Streptoseomycin (streptoseomycin) can optionally suppress Lactobacterium acidophilum (clinical strain), bifidus bacillus (clinical strain), Eubacterium brachy (clinical strain), propionibacterium (ATCC6919) and propionibacterium (ATCC11827).
The anti-anaerobic activity of table 2 compound streptoseomycin
Table?2.the?antimicrobial?susceptibility?testing?of?anaerobic?bacteria?of?streptoseomycin
* with the positive contrast of gentamicin sulphate (Gentamicin)
Above results suggest, Streptoseomycin (streptoseomycin) has very strong anti-anaerobic activity and has certain selectivity, and therefore Streptoseomycin of the present invention can be developed into new antibiotic.
Claims (4)
1. Seoul streptomycete, it is characterized in that: on the PDA flat board, the bacterium colony characteristic feature is the substrate mycelium yellow, easily produces single bacterium colony, the discontinuous aerial hyphae beige of ruling, spore white; On Martin's substratum, the substrate mycelium beige, aerial hyphae white, the spore beige, bacterium colony produces flower-shaped edge; On the Gause I flat board, the substrate mycelium beige, aerial hyphae white, the spore beige, bacterium colony produces flower-shaped edge; State is more special on the Cha Shi substratum, and substrate mycelium is light yellow, the bright orange green of aerial hyphae, spore brown.Be accredited as Seoul streptomycete Streptomyces seoulensis through Institute of Microorganism, Academia Sinica, now be deposited in DSMZ of Institute of Microorganism, Academia Sinica, address: Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, deposit number is CGMCC No.3689, and preservation date is on March 25th, 2010.
2. according to the Streptoseomycin of the described Seoul of claim 1 streptomycete fermentation liquid preparation, it is characterized in that structural formula is:
3. the preparation method of Streptoseomycin streptoseomycin according to claim 2 is characterized in that being made of following steps:
1) fresh Seoul streptomycete Streptomycesseoulensis mycelium piece that separation, purifying obtain from prawn Penaeus chinensis enteron aisle is inoculated in the Gao Shi I substratum, on shaking table, under 150rpm, 28 ℃ of conditions, cultivate 5 days as seed liquor; Gao Shi I substratum: Zulkovsky starch 20g, KNO
31g, NaCl 0.5g, K
2HPO
43H
2O0.5g, MgSO
47H
2O 0.5g, FeSO
47H
2O 0.01g, 1L distilled water;
2) then seed liquor is inoculated in Gao Shi or the Martin's substratum, 150rpm, 20-30 ℃ of condition bottom fermentation 8 days;
3) step 2 gained fermented liquid is filtered through gauze, filtrate is used ethyl acetate extraction, the dry black crude extract F1 that gets of vacuum concentration;
4) crude extract F1 is suspended in water, uses sherwood oil, ethyl acetate extraction successively, the gained acetic acid ethyl acetate extract through concentrate medicinal extract F2;
5) medicinal extract F2 is carried out silica gel column chromatography, use the chloroform of 4 times of volumes earlier successively, chloroform: methyl alcohol=100: 1, chloroform: methyl alcohol=100: 2, chloroform: methyl alcohol=100: 4, carry out wash-out, concentrate 100: 4 sections and obtain black medicinal extract F3;
6) then medicinal extract F3 is carried out Sephadex LH-20 and separate the elutriant chloroform: methyl alcohol volume ratio 1: 1 merges green fluorescence part elutriant and gets faint yellow medicinal extract F4;
7) to medicinal extract F4, ODS separates with reversed-phase column, carries out wash-out with 55% methyl alcohol earlier and removes the decyclization dipeptides, uses 65% methanol-eluted fractions then, merges green fluorescence part elutriant and gets faint yellow solid F5;
8), prepare Streptoseomycin streptoseomycin with high pressure lipuid chromatography (HPLC) to medicinal extract F5.
4. the application of Streptoseomycin streptoseomycin according to claim 2 in the preparation antibiotic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010180437XA CN101892181B (en) | 2010-05-24 | 2010-05-24 | Streptoseomycin and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010180437XA CN101892181B (en) | 2010-05-24 | 2010-05-24 | Streptoseomycin and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101892181A true CN101892181A (en) | 2010-11-24 |
| CN101892181B CN101892181B (en) | 2012-06-27 |
Family
ID=43101529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010180437XA Expired - Fee Related CN101892181B (en) | 2010-05-24 | 2010-05-24 | Streptoseomycin and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101892181B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110041401A (en) * | 2019-03-14 | 2019-07-23 | 南京大学 | Ken Tasenna mycin and its preparation method and application |
| CN112763592A (en) * | 2020-12-15 | 2021-05-07 | 上海明捷医药科技有限公司 | Method for measuring content of streptomycin in protein solution |
| CN113637603A (en) * | 2021-07-12 | 2021-11-12 | 南京大学 | Intestinal lactobacillus for endowing food ingredients with anticancer effect and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101636487A (en) * | 2007-01-19 | 2010-01-27 | 艾克沃制药生物发明有限公司 | Inducing of microbial secondary metabolites |
-
2010
- 2010-05-24 CN CN201010180437XA patent/CN101892181B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101636487A (en) * | 2007-01-19 | 2010-01-27 | 艾克沃制药生物发明有限公司 | Inducing of microbial secondary metabolites |
Non-Patent Citations (3)
| Title |
|---|
| 《International journal of systematic bacteriolog》 19970430 J Chun et al Streptomyces seoulensis sp.nov. 第492-498页 1-4 第47卷, 第2期 2 * |
| 《中国抗生素杂志》 20090331 胡申才等 获自链霉菌060524发酵液细胞毒活性物质 第s1-s3页 1-4 第34卷, 第3期 2 * |
| 《药物生物技术》 20061231 谷俊等 海洋放线菌M324抗菌物质的发酵优化与性质的初步研究 第347-350页 1-4 第13卷, 第5期 2 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110041401A (en) * | 2019-03-14 | 2019-07-23 | 南京大学 | Ken Tasenna mycin and its preparation method and application |
| CN110041401B (en) * | 2019-03-14 | 2022-09-23 | 南京大学 | Kentanson namycin, preparation method and application thereof |
| CN112763592A (en) * | 2020-12-15 | 2021-05-07 | 上海明捷医药科技有限公司 | Method for measuring content of streptomycin in protein solution |
| CN113637603A (en) * | 2021-07-12 | 2021-11-12 | 南京大学 | Intestinal lactobacillus for endowing food ingredients with anticancer effect and application thereof |
| CN113637603B (en) * | 2021-07-12 | 2023-07-25 | 南京大学 | Lactobacillus entericus and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101892181B (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102181387B (en) | Streptomyces sp. and method for preparing straurosporine and K-252d by utilizing Streptomyces sp. | |
| CN107353274B (en) | Selenolonic acid I from penicillium oxalicum and application thereof in preparation of human esophageal cancer resistant medicine | |
| CN102311981B (en) | Method for preparing and purifying prodigiosin | |
| CN103910708A (en) | Marine fungus-derived Azaphilones compound, and preparation method and application thereof | |
| CN103910746A (en) | Marine fungus-derived Berkeleyones compound, and preparation method and application thereof | |
| CN106432262A (en) | Streptomyces-derived halogenated polyketide compound, preparation method and application | |
| CN101892181B (en) | Streptoseomycin and preparation method and application thereof | |
| CN109134574B (en) | Steroid compound, preparation method and application thereof, and anti-tumor drug | |
| CN102030753B (en) | Prenylated indole alkaloids and preparation method and application thereof | |
| CN103910701A (en) | Marine fungus-derived naphthoquinone compound, and preparation method and application thereof | |
| CN103911407A (en) | Marine fungus-derived Azaphilone dimer compound, and preparation method and application thereof | |
| CN114213428B (en) | Indole alkaloid compound and preparation method and application thereof | |
| CN102965300B (en) | Micromonospora strain, its preparation method and application | |
| CN109134416B (en) | Application of seclenic acid H derived from penicillium oxalicum in preparation of human cervical cancer drugs | |
| CN103145740B (en) | Sulfoxide alkaloid compound as well as preparation method and application for same | |
| CN102757443B (en) | Sulfur-substituted podophyllum derivative and bioconversion, separation and purification method thereof | |
| CN102051394A (en) | Preparation method and application of sulfo-diketopiperazine compounds | |
| CN107226800A (en) | A kind of xanthone classes compound and its preparation method of monocrystalline and the application as anti-Mycobacterium marinum medicine | |
| CN109134417B (en) | Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human cervical cancer | |
| CN110452940A (en) | A kind of separating and extracting process of the secondary metabolite of streptomycete | |
| CN101496820B (en) | Active extract of facultative anaerobic sea Pseudomonas stuszeri as well as production method and use thereof | |
| CN103408557B (en) | Indolizidine alkaloid as well as preparation method and application thereof | |
| CN107973803A (en) | A kind of seven yuan of lactone benzofuran derivs and its preparation method and application | |
| CN103570652A (en) | Epoxy benzoanthraquinone compound as well as preparation method and application thereof | |
| CN104447475B (en) | Preparation method and application of penicillenol D1 derived from penicillium citrinum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20150524 |
|
| EXPY | Termination of patent right or utility model |